Takeda casts a new line with first DTC campaign for HyQvia in CIDP
Takeda kicked off 2024 by reeling in an approval for HyQvia in chronic inflammatory demyelinating polyneuropathy (CIDP), and it’s closing out the year by launching its first direct-to-consumer campaign for the new indication. CIDP is a rare autoimmune …